Abstract
Two types of Klebsiella pneumoniae (KP) strains are currently emerging: hypervirulent (hvKP) strains and carbapenem-resistant (CR-KP) strains. To date, these two strain types rarely overlap. Recent reports, however, suggest that CR-KP strains are increasing in virulence. hvKP strains frequently present as highly invasive infections, such as necrotizing skin and soft tissue infections (NSSTI). To examine whether CR-KP strains with features of hvKP were present in our U.S. hospital, we retrospectively identified four cases of CR-KP NSSTI diagnosed between January 2012 and January 2016. Whole-genome sequencing was used to perform multilocus sequence typing, capsular typing, and identification of virulence and antimicrobial resistance genes. Additionally, the virulence of each isolate was determined in vitro and using murine pneumonia and subcutaneous infection models. We identified one CR-KP isolate that possessed features of hypervirulent KP, including a hypermucoviscous phenotype, K2 capsule, and resistance to phagocytosis. Of the four CR-KP isolates, two had no evidence of enhanced pathogenicity in either mouse model, demonstrating that low-virulence strains can cause NSSTI in immunosuppressed patients. The remaining two isolates exhibited low virulence in the pneumonia model but high virulence in the subcutaneous infection model, suggesting that the virulence attributes of these isolates are adapted to causing NSSTI.
Introduction
Over the last several decades, Klebsiella pneumoniae (KP) has emerged as a cause of community-acquired invasive infections such as necrotizing skin and soft tissue infections (NSSTI), pyogenic liver abscesses, endophthalmitis, and meningitis. The KP strains that cause these infections, referred to as “hypervirulent KP” (hvKP)1, were initially noted in Taiwan. Since these early reports, hvKP infections have continued to increase in incidence in Taiwan and have spread across Asia, dramatically changing the epidemiology of many infections in this region of the world. For example, in Taiwan more than 3000 cases of pyogenic liver abscesses now occur each year2, of which 80% are caused by KP3. In this same country, hvKP causes as many cases of necrotizing fasciitis as Streptococcus pyogenes and is associated with a substantially higher mortality (47% vs. 19%)4. Importantly, hvKP infections are now being reported around the globe4–8, including in North America7,9.
hvKP strains appear to be distinct from classical KP (cKP) strains in several microbiological aspects. hvKP isolates frequently have K1 or K2 capsule serotypes10,11 and produce large amounts of capsule exopolysaccharide, which results in a hypermucoviscous phenotype when cultured on solid agar. A common feature associated with hvKP is the presence of a large virulence plasmid encoding a number of virulence factors, including a regulator contributing to the hypermucoviscous phenotype (RmpA/A2) and the siderophores aerobactin and salmochelin12,13. Additional features associated with hvKP include a ferric uptake operon (kfuABC) and an integrative and conjugative element (ICEKp1) encoding the yersiniabactin siderophore system and colibactin14,15. Despite the association of particular genetic and phenotypic features with hvKP, studies have noted many exceptions16,17. As such, no definitive test to distinguish between cKP and hvKP currently exists.
hvKP isolates have remained generally susceptible to most antibiotics except ampicillin18,19. In an early study of community-acquired KP bacteremia (many of which were presumed to be caused by hvKP), only 3.5% of strains produced extended spectrum ß-lactamases (ESBLs)20. Coincident with the spread of hvKP has been a rapid and concerning emergence of carbapenem-resistant KP (CR-KP) worldwide. CR-KP strains are now relatively common and pose a frequent therapeutic challenge to physicians. Because patients infected with these strains frequently receive inadequate empiric and definitive antibiotic therapy, they experience mortality rates of 23-75%21,22. Fortunately, CR-KP strains have typically been of low virulence and not associated with invasive infections such as NSSTI. In general, these CR-KP isolates have demonstrated low virulence in mouse models of infection and are susceptible to phagocytosis23. However, a few cases of NSSTI caused by CR-KP have appeared in the recent literature24, raising concerns for the emergence of KP clones that combine multidrug-resistance with a high degree of virulence. This concern is further reinforced by recent case reports of multidrug-resistant hvKP, mostly from Asia25,26–including the first cases of carbapenem-resistant hvKP infection27–29. To our knowledge, no cases of MDR hvKP have been reported in the U.S. to date. However, highly virulent CR-KP strains may go unrecognized because clinical microbiology laboratories do not routinely screen for the hypermucovisous or hvKP phenotypes. Consequently, virulence characterization of CR-KP strains associated with invasive disease, such as NSSTI, could reveal hypervirulence not detected in CR-KP to date.
We recently identified a case of NSSTI caused by CR-KP at our hospital, a U.S. tertiary care medical center. Since NSSTI is a known manifestation of hvKP, this caused concern that this KP strain might have combined carbapenem-resistance with hypervirulence. To address this concern, we performed a retrospective chart review of all NSSTI cases caused by CR-KP over a four-year period, which identified three additional cases. Here, we describe the clinical, demographic, and antibiotic susceptibility features of these four cases. These four isolates were also tested for a variety of virulence traits in vitro, including hypermucoviscosity, capsule production, and phagocytosis resistance. Furthermore, we assessed the in vivo virulence potential of each isolate using both pneumonia and subcutaneous murine infection models. From these studies, we identified one CR-KP NSSTI isolate (NU-CRE265) that exhibited several characteristics consistent with hvKP.
Results
Clinical characteristics and outcomes of patients diagnosed with CR-KP NSSTI
A retrospective chart review of all cases of KP NSSTI diagnosed at our institution between January 2012 and January 2016 identified four cases of CR-KP NSSTI. The KP isolates from these patients were designated NU-CRE101, NU-CRE176, NU-CRE212, and NU-CRE265. The mean age was 52 years and the mean modified SOFA score was 4 (Table 1). Patients were immunosuppressed (3/4) and/or had diabetes mellitus (2/4). All cases received adequate surgical and antibiotic treatment (Table 1 and Table S1). Although in-hospital mortality was 0%, two patients had relapse of infection requiring readmission, two patients died after discharge, and one of these deaths was a result of the relapse. Thus, the overall-mortality was 50% and the infection-attributable mortality was 25%.
Table 1.
NU-CRE101 | NU-CRE176 | NU-CRE212 | NU-CRE265 | |
---|---|---|---|---|
Clinical Characteristics | ||||
Age, Sex | 69, M | 50, F | 46, M | 43, M |
Charlson Score | 6 | 4 | 6 | 6 |
Specific Comorbidities | Bladder cancer on chemotherapy | Myasthenia gravis on chronic corticosteroids | DM, CKD on dialysis, failed kidney and pancreas transplant on IS | DM, CKD on dialysis |
Immunosuppresed | Yes | Yes | Yes | No |
Community-acquired infection | No | Yes | No | No |
Post-surgical Infection | No | No | Yes | Yes |
Modified SOFA score | 2 | 4 | 7 | 4 |
Fever/Hypotension | Yes/No | No/Yes | Yes/Yes | No/No |
Microbiologic characteristics | ||||
Culture source | Tissue | Tissue/Blood | Tissue | Tissue |
Polymicrobial culture | VRE | No | MSSA | No |
Meropenem Susceptibility | R (>16) | R (>16) | R (>16) | R (>16) |
Management | ||||
Source control achieved (surgery) | Yes | Yes | Yes | Yes |
Time to effective antibiotic (hs) | 39.8 | 80.7 | 70.8 | 131.1 |
Duration of effective antibiotic (days) | 19 | unknowna | 28 | unknownb |
Outcomes | ||||
Length of hospital stay (days) | 23 | 6 (transferred) | 13 | 55 |
In-hospital death | survived | survived | survived | survived |
Relapse | No | after 5 months | after 4 months | No |
Overall death (post-discharge) | Yes | Yes | No | No |
Death attributable to infection | No | Yes | No | No |
DM, diabetes mellitus; CKD, chronic kidney disease; IS, Immunos supressants; VRE, vancomycin-resistant Enterococcus spp.; MSSA, methicillin-susceptible Staphylococcus aureus.
aTotal duration of effective antibiotic treatment is unknown, because the patient was transferred to another facility after 6 days of treatment.
bTotal duration of effective antibiotic treatment is unknown, because the patient was transferred to a rehabilitation facility and had no follow up at our institution.
Genotypes of CR-KP NSSTI isolates
CR-KP isolates have been associated with globally disseminated clones. To assess the genotypes of the four CR-KP NSSTI isolates, in silico multilocus sequence typing (MLST) was performed. Two of the 4 isolates belonged to the globally disseminated MLST group ST258 and one (NU-CRE265) belonged to the ST14 group; ST258 and ST14 have both been previously associated with multidrug-resistant KP outbreaks30,31. The fourth isolate belonged to ST1082.
CR-KP NSSTI isolates carried KPC carbapenemases and a variety of virulence genes
Two main mechanisms of carbapenem resistance have been described among KP strains: production of carbapenemases or production of other ß-lactamases in association with permeability defects of the bacterial cell envelope32. In contrast, multiple genes have been associated with increased virulence among KP strains. Whole genome sequencing was used to identify antibiotic resistance determinant genes (including ß-lactamase and carbapenemase genes) carried by the CR-KP strains and to identify virulence genes previously described as associated with hvKP strains. Publicly available databases containing a comprehensive collection of these genes were used for these purposes, as described in the Methods section. As controls, we used the previously characterized low-virulence, non-hypermucoviscous strain MGH78578 and the hypervirulent, hypermucoviscous strain NTUH-K2044. All 4 CR-KP NSSTI isolates carried one carbapenemase gene (blaKPC-2 or blaKPC-3) in addition to at least one other ß-lactamase gene (Table 2). Virulence genes previously found in hvKP strains were also assessed, including the rmpA/A2 gene (regulator of mucoid phenotype), fimbrial genes, genes for the biosynthesis or uptake of iron (such as aerobactin, enterobactin, yersiniabactin, and salmochelin)12–15,26,33, and for the biosynthesis of the genotoxin colibactin33. All CR-KP NSSTI isolates carried type 1 and type 3 fimbrial genes. They also carried genes involved in the synthesis of enterobactin, as well as the aerobactin receptor gene (iutA). The presence of other virulence factors associated with iron-acquisition systems (yersiniabactin and kfuABC) and colibactin was variable across isolates (Table 2 and Fig. S1).
Table 2.
NTUH-2044 | MGH78578 | NU-CRE101 | NU-CRE176 | NU-CRE212 | NU-CRE265 | |
---|---|---|---|---|---|---|
String test | + | − | − | − | − | + |
MLST | ST23 | ST38 | ST1082 | ST258 | ST258 | ST14 |
Capsule Serotype | K1 | K52 | K51 | non-typable | non-typable | K2 |
Virulence factors | ||||||
Capsule up-regulation | ||||||
rmpA | + | − | − | − | − | − |
rmpA2 | + | − | − | − | − | − |
Siderophore systems | ||||||
Enterobactin (entABCDEF) | + | + | + | + | + | + |
Aerobactin (iucABCD) | + | − | − | − | − | − |
Aerobactin receptor (iutA) | + | + | + | + | + | + |
Yersiniabactin (ybt and irp complex) | + | − | − | + | + | − |
Yersiniabactin receptor (fyuA) | + | − | − | + | + | − |
Salmochelin (iroBCD) | + | − | − | − | − | − |
Salmochelin receptor (iroN) | + | + | + | + | + | + |
Genotoxin | ||||||
Colibactin (clbA to clbR) | − | − | − | + | + | − |
Fimbrial genes | ||||||
Type 3 fimbrial adhesion genes | + | + | + | + | + | + |
Type 1 fimbrial adhesion genes | + | + | + | + | + | + |
Other genes | ||||||
kfuABC | + | − | + | − | − | + |
allABCDRS | + | − | − | − | − | − |
Antibiotic resistance genes | ||||||
Beta-lactamases | SHV-11 | SHV-11 | KPC-2 | KPC-3 | KPC-3 | KPC-3 |
SHV-1 | SHV-11 | SHV-11 | SHV-28 | |||
TEM-1 | TEM-1A | OXA-9 | ||||
OXA-9 | ||||||
Aminoglycosides resistance genes | − | − | aadA1 | aadA1 | aph(3′ )-Ia | aadA1 |
aac(3)-I | aac(6′ )Ib | aac(6′)Ib | aac(6′ )Ib | |||
aacA4 | strA, strB | aadA2 | strA, strB | |||
Fluoroquinolones resistance genes | oqxA, oqxB | oqxA, oqxB | oqxA, oqxB | oqxA, oqxB | oqxA, oqxB | oqxA, oqxB |
aac(6′ )Ib-cr | aac(6′ )Ib-cr | aac(6′ )Ib-cr | aac(6′ )Ib-cr | |||
Other resistance genes | fosA | fosA | fosA, sul1, | fosA, sul2, | fosA, sul1, | fosA, sul1, |
tet(D), dfrA1 | dfrA14 | dfrA12, catA1 | sul2, dfrA14 |
MLST, multilocus sequence typing. “+” indicates that gene was present, “−” indicates that gene was absent.
*A complete list of the genes involved in the synthesis of these virulence factors can be found in the Supplementary Figure S1.
Capsule typing and production
Capsular serotypes K1 and K2 have been associated with the hypervirulent phenotype18,34. To identify the capsule types of the CR-KP isolates in our study, we performed in silico capsular polysaccharide (CPS) genotyping using the wzc sequence as previously described35. A K2 capsular genotype was identified for the CR-KP NSSTI isolate NU-CRE265. The other 3 isolates had a K51 or non-typeable capsular genotype (Table 2). In addition to capsular genotype, hypermucoviscosity and increased capsule production have been associated with highly virulent KP strains36,37. We first examined the NSSTI isolates for differences in hypermucoviscosity by the string test method. Only one isolate, NU-CRE265, was found to have a positive string test. We next determined the amount of CPS produced by the NSSTI isolates using an uronic acid quantification assay (Fig. 1). We again used the low-virulence, non-hypermucoviscous strain MGH78578 and the hypervirulent, hypermucoviscous strain NTUH-K2044 as controls. In agreement with previous reports, NTUH-K2044 produced significantly more CPS than MGH78578 (0.053 vs. 0.031 μg/106 CFU, p < 0.05)38. Among the NSSTI isolates, only NU-CRE265 produced more capsule than MGH78578 (0.065 μg/106 CFU, p < 0.05 compared to MGH78578). In fact, capsule levels for NU-CRE265 were higher than all the other strains, including NTUH-K2044, consistent with the hypermucoviscous phenotype assigned to this isolate.
Phagocytic uptake of CR-KP NSSTI isolates
CPS has been demonstrated to shield KP from phagocytosis and killing by immune cells and in this way contributes to heightened virulence36. Indeed, hvKP strains are more resistant to neutrophil-mediated killing than classical KP strains17. We evaluated the resistance of the CR-KP NSSTI isolates to phagocytic uptake by the J774 macrophage-like cell line (Fig. 2). Three of the CR-KP NSSTI isolates (NU-CRE101, NU-CRE176, and NU-CRE212) were phagocytosed to a similarly high degree as the low-virulence strain MGH78578. In contrast, both NU-CRE265 and the hypervirulent control strain NTUH-K2044 were highly resistant to phagocytic uptake compared to MGH78578 (p < 0.05). These data are consistent with the high levels of CPS production and the hypermucoviscous phenotype of NU-CRE265 conferring protection from phagocytic uptake.
Virulence of NSSTI CR-KP isolates in a murine pneumonia model
Although in vitro attributes of bacterial isolates are important indicators of their ability to cause severe infections, the true measure of overall virulence is captured by animal models. To investigate the in vivo pathogenic potential of the CR-KP NSSTI isolates, we first utilized a murine acute pneumonia model, which has been commonly used to quantify K. pneumonia virulence38. Mice were infected with either 5 × 106 CFU or 5 × 107 CFU of the CR-KP NSSTI isolates, MGH78578, or NTUH-K2044. Compared to the NTUH-K2044 infected control group, which exhibited 100% mortality by 96 h post-infection, mice infected with the CR-KP NSSTI isolates or MGH78578 exhibited 100% survival out to 14 days post-infection at both tested doses (data not shown). We further examined the bacterial burden in the lungs as well as dissemination to the liver at 96 h post-infection. Consistent with previous reports, the hvKP control strain NTUH-K2044 exhibited proliferation in the lungs and dissemination to the liver38 (Fig. 3). In contrast, all the CR-KP NSSTI isolates, as well as the low-virulence strain MGH78578, were cleared from the lungs and failed to disseminate to the liver at both tested doses (Fig. 3). These results indicate that the CR-KP NSSTI isolates have a relatively low level of virulence in a mouse pneumonia model.
Virulence of NSSTI CR-KP isolates in a mouse subcutaneous infection model
Since the CR-KP NSSTI isolates were originally isolated from skin and soft tissue infections, we next investigated the virulence potential of the isolates using a mouse subcutaneous infection model. Mice were infected subcutaneously with 5 × 106 CFU of the CR-KP NSSTI isolates or the control strains MGH78578 and NTUH-K2044, and disease progression was monitored over a 96 h period. In agreement with previous studies, subcutaneous inoculation of KP was found to induce abscess formation within the subcutaneous tissue, which could be quantified by measuring the surface area of the resulting abscess17,39. Inoculation with the hypervirulent control strain NTUH-K2044 resulted in the largest abscesses with occasional extension to cause necrosis of the skin, while the low-virulence control MGH78578 induced only small abscess formation and no necrotic lesions (Fig. 4A and Fig. S2). The CR-KP NSSTI isolates varied dramatically in the subcutaneous infection model. NU-CRE265 and NU-CRE176 formed significantly larger abscesses than MGH78578 and the remaining CR-KP NSSTI isolates (Fig. 4A and Fig. S2). In addition to abscess development, we quantified the bacterial burdens within the subcutaneous tissue and livers. Similar to the hypervirulent NTUH-K2044 control, both NU-CRE265 and NU-CRE176 exhibited increased bacterial burdens in the skin and subcutaneous tissue as well as dissemination to the liver at 96 h post-infection (Fig. 4B and C, respectively). These data suggest that both NU-CRE265 and NU-CRE176 exhibit enhanced virulence during skin and soft tissue infection.
Previous reports have demonstrated a critical role for neutrophils in promoting clearance of KP during animal infection40,41. Additionally, KP skin infection has been shown to result in the extensive infiltration of neutrophils at the infection site39.To further characterize the skin and soft tissue abscesses induced by CR-KP infection, we next examined the host response at 24 h post infection. We performed flow cytometry to quantify the total and specific infiltrating immune cells in the abscess tissue during infection with the virulent NSSTI isolate NU-CRE265. Compared to mock-infected mice, NU-CRE265 infected mice exhibited a robust increase in the total number of immune cells and the number of neutrophils recovered from the abscess tissue (Fig. S3).
Considering that the CR-KP NSSTI isolates were obtained from immunocompromised patients, we examined whether the potential of these isolates to cause subcutaneous infections was enhanced by neutropenia. Mice were treated with either an isotype control antibody (IgG) or an anti-Ly6G antibody to systemically deplete neutrophils, and then infected subcutaneously with the CR-KP NSSTI isolates or control strains. To confirm the depletion of neutrophils from the Ly6G-treated mice, we performed immune cell staining and flow cytometry on the excised abscess tissue. Ly6G-treated mice exhibited a decrease in total neutrophils and an increase in total macrophages and monocytes in the abscess tissue compared to the IgG-treated control group (Fig. S3). Neutrophil depletion resulted in an overall increase in abscess lesion size (Fig. 5A and Fig. S4), as well as increased bacterial burdens and dissemination to the liver for all CR-KP NSSTI isolates (Fig. 5B and C). However, upon neutrophil depletion, only NU-CRE176 and NU-CRE265 produced abscess lesions comparable to the highly virulent NTUH-K2044 control (48 ± 4 mm2 and 46 ± 2 mm2 vs. 48 ± 2 mm2, respectively; p > 0.05) (Fig. 5A). Additionally, NU-CRE176 and NU-CRE265 exhibited increased bacterial numbers in the abscess (9.3 × 107 and 4.4 × 107 CFU, respectively) and dissemination to the liver (2.7 × 103 and 5.7 × 104 CFU, respectively) at levels similar to the NTUH-K2044 control (abscess = 2.6 × 108 CFU; liver = 2.2 × 104 CFU) (Figs. 5B and C). Interestingly, NTUH-K2044 caused abscesses of similar size and with similar numbers of bacteria regardless of neutropenia (Fig. 5), suggesting that this strain is not affected by the antibacterial functions of neutrophils. Together, these results demonstrate that two of the CR-KP NSSTI isolates, NU-CRE176 and NU-CRE265, exhibit in vivo virulence phenotypes similar to highly virulent KP in a subcutaneous infection model. Furthermore, these findings demonstrate the utility of the mouse subcutaneous infection model for identifying and characterizing highly virulent strains of KP and suggest that some KP strains may be adapted to preferentially infect certain tissue types.
Capsule production is required for KP persistence during skin infection
Capsule plays an important role in preventing neutrophil-mediated clearance of KP and represents one of the most significant virulence determinants of this bacterium. In a mouse model of KP pulmonary infection, capsule was required for bacterial colonization and persistence42. However, the role of capsule in KP pathogenicity during skin and soft tissue infection has yet to be determined. To investigate the impact of capsule production in the subcutaneous infection model, we generated a capsule mutant in the hypermucoviscous and highly virulent NSSTI isolate NU-CRE265. The entire K2 capsule biosynthesis cluster of genes was deleted from NU-CRE265 to generate NU-CRE265Δcps (see Supplementary Methods), and the loss of capsule production was confirmed by measurement of the uronic acid content (Fig. S5). We next assessed the sensitivity of the NU-CRE265Δcps mutant to phagocytic uptake by J774 macrophage-like cells. As expected, NU-CRE265Δcps exhibited increased phagocytic uptake compared to the parental NU-CRE265 strain (21.1% vs. 1.1% uptake, respectively; p < 0.05) (Fig. S5). To assess the contribution of capsule during skin and soft tissue infection, we subcutaneously infected both neutrophil-replete (IgG isotype control treated) and neutrophil depleted (anti-Ly6G treated) mice with either the parental NU-CRE265 strain or the NU-CRE265Δcps mutant. In IgG-treated mice, NU-CRE265Δcps infection resulted in dramatically reduced abscess formation at 96 h post-infection (Fig. 6A). NU-CRE265Δcps also failed to proliferate within the subcutaneous tissue and to disseminate to the liver in IgG-treated mice (Fig. 6B and C, respectively). In contrast, NU-CRE265Δcps caused large skin abscesses in neutropenic (Ly6G-treated) mice, albeit smaller than the abscesses resulting from infection of neutropenic mice with the parental strain (34.8 ± 7.5 mm2 vs. 54.4 ± 9.9 mm2, respectively; p > 0.05) (Fig. 6A). Likewise, NU-CRE265Δcps bacteria were found in substantial numbers within the abscesses and livers of neutropenic mice at 96 h post infection (Fig. 6B, and C, respectively). In fact, infection of neutrophil-depleted mice with bacteria lacking capsule nicely phenocopied infection of neutrophil-replete mice with wild-type bacteria in abscess size, abscess CFU, and liver CFU. These data indicate that the capsule of KP functions to counteract the sterilizing effects of neutrophils in the mouse subcutaneous infection model.
Discussion
KP has been recognized as an emerging threat to human health due in part to the rise in multi-drug resistant isolates as well as hypervirulent strains capable of causing invasive infections. To date, these two groups of KP strains have remained largely distinct, but there is concern that strains both highly virulent and highly resistant to antibiotics are emerging. NSSTI are rarely caused by KP but have been identified as one of the clinical manifestations associated with hvKP. Thus, these infections may indicate the presence of hvKP strains. The aim of this study was to identify cases of NSSTI caused by CR-KP among hospitalized patients in a tertiary medical center in the U.S. and to perform a comprehensive evaluation of the virulence of these strains to determine whether they were both CR-KP and hvKP. During the 4-year period, CR-KP caused invasive disease in the form of NSSTI in four patients. A comprehensive virulence assessment demonstrated a range of virulence profiles among the NSSTI CR-KP isolates. While some isolates exhibited low virulence, others demonstrated some features of hvKP such as increased capsule production, resistance to phagocytosis and potential for bacterial dissemination. Moreover, two CR-KP NSSTI isolates were as virulent as a hvKP control strain in the mouse subcutaneous infection model but not in the pneumonia model, suggesting that these strains are adapted to cause more severe skin and soft tissue infections.
We identified one NSSTI CR-KP isolate, NU-CRE265, that exhibited several features previously associated with hvKP. This isolate produced a K2 capsule–a common virulence determinant of hvKP–and was both hypermucoviscous (string test positive) and highly virulent in the mouse subcutaneous infection model. The hypermucoviscosity phenotype was confirmed to be secondary to capsular polysaccharide overproduction. However, the genetic drivers of capsule overproduction in NU-CRE265 appear to differ from those commonly associated other hvKP strains, as this isolate lacked both of the known capsule regulatory genes rmpA and rmpA2. Hypermucoviscous hvKP strains that lack rmpA and rmpA2 have been previously described, but the mechanisms by which they overexpress their capsules remain unknown43,44. NU-CRE265 also carried an intact kfu locus (iron uptake system), which has been previously reported in hvKP isolates from pyogenic liver abscesses15. However, it lacks other well-characterized virulence factors associated with hvKP, such as allantoin metabolism (the allS gene) and the yersiniabactin and aerobactin siderophore systems45,46. Of note, 10% and 7–15% of hvKP-like isolates lack yersiniabactin and aerobactin genes, respectively47–50, and one study found that the deletion of the genes for yersiniabactin or aerobactin utilization did not impact hvKP virulence in a mouse model47. It therefore appears that some hvKP strains have traits that allow them to cause severe invasive infections even in the absence of several of the genes commonly associated with the hypervirulence phenotype. NU-CRE265 may be one of these strains.
In this study, we investigated the virulence potential of the CR-KP NSSTI isolates using mouse pneumonia and subcutaneous infection models. Both these models have been used previously to characterize hvKP strains38,51, and pneumonia and NSSTI are both clinical manifestations associated with hvKP19,20,52. Intriguingly, while all four CR-KP isolates were relatively avirulent in the mouse pneumonia model, two isolates (NU-CRE176 and NU-CRE265) exhibited virulence phenotypes similar to the hvKP strain NTUH-K2044 in the subcutaneous model. Upon subcutaneous infection, these virulent CR-KP isolates induced the formation of large abscesses and occasional necrotic skin lesions, while also exhibiting increased proliferation within the subcutaneous tissue and enhanced dissemination to the liver. These virulence phenotypes are consistent with those reported in previous studies examining the pathogenesis of KP and other NSSTI-causing pathogens such as Staphylococcus aureus in skin and soft tissue infections39,53,54. Together, these data suggest that the concept of hvKP may be overly simplified, and that some strains may have the potential to manifest as hvKP in certain tissues but not in others. Indeed, preliminary studies indicate that NU-CRE265 also exhibits low virulence in a mouse intraperitoneal infection model, as indicated by 100% mouse survival upon infection with 5 × 106 CFU of NU-CRE 265 (data not shown), further suggesting that the relative virulence of NU-CRE265 is dependent upon the route or site of infection. The mechanisms underlying the enhanced virulence of the two CR-KP isolates in the subcutaneous infection model compared to the pneumonia model remain unknown. Both NU-CRE176 and NU-CRE265 carried intact loci encoding for type 1 (fimA to fimK) and type 3 (mrkABCDF) fimbrial adhesion genes, and the enterobactin siderophore (entABCDEF). While some studies have reported these genes as ubiquitous among clinical KP strains, with prevalence of 95-100%52,55, other studies have reported differences in the prevalence based on capsule genotype, hypermucoviscous phenotype and source of infection. For example, mrkD has been reported as highly prevalent among K2 strains, hypermucoviscous strains and urine samples, but absent in K1, non-hypermucoviscous strains and respiratory samples56,57. In our study, these genes were found in all NSSTI CR-KP isolates. Therefore, it is unlikely that these factors are by themselves responsible for the high virulence in the subcutaneous infection model evidenced only in two of the isolates. While other important virulence factors such as yersiniabactin, colibactin and kfuABC were found in half of the NSSTI isolates, they did not explain the difference in virulence seen in the subcutaneous infection model, since they were found in one isolate with high virulence and one with low virulence. Furthermore, other important virulence factors were lacking, such as the capsule regulatory genes rmpA/A2, and K1/magA, aerobactin, salmochelin, and allantoin metabolism genes. It remains possible that these CR-KP isolates have acquired uncharacterized virulence factors that compensate for the absence of these known virulence factors. Alternatively, several of these hvKP-associated virulence factors may be required for establishing infection in the lungs or dissemination to the liver but may be dispensable during subcutaneous infection58,59. Regardless of the explanation, our findings suggest that some KP strains may be better adapted to infect certain tissues than others. Comparative genomics analysis has been performed in the past to detect novel virulence factors60. Future studies, with a larger number of strains, could use this approach to compare strains with site-selective virulence and identify site-specific virulence factors.
While the exact set of virulence factors required for hypervirulence in the subcutaneous infection model remains unknown, our studies did identify a critical role for capsule production, as a capsule-defective mutant of NU-CRE265 failed to establish infection and persist within the subcutaneous tissue. The requirement for capsule production during subcutaneous infection was largely dependent on the presence of host neutrophils. In neutropenic mice, the capsule mutant was fully capable of inducing abscess formation and proliferating within the tissue. These findings are consistent with previous studies demonstrating that capsule inhibits KP uptake and clearance by phagocytic cells. Additionally, this work demonstrates the critical role of neutrophils in preventing KP strains from causing NSSTIs. Indeed, even low virulence CR-KP isolates (NU-CRE101 and NU-CRE212) were capable of inducing abscess formation and proliferating in the subcutaneous tissue in neutropenic mice, suggesting that in an immunocompromised host low-virulence strains of KP can cause NSSTIs. These findings suggest that the development of NSSTIs depends upon both the virulence of the KP strain and the immune status of the host. Highly immunocompromised patients may develop NSSTI following infection with even low-virulence KP strains, whereas patients with relatively intact immune systems may develop NSSTI only after exposure to more virulent KP strains. In this regard, it is interesting that NU-CRE265, the strain with features of hvKP, was cultured from the only patient in our series that was not on immune-suppressive therapy (Table 1).
The merging of CR-KP and hvKP is a dreaded development that would result in large numbers of patients with infections that were both severe and difficult to treat. Recent reports indicate that such strains are emerging in Asia25,26,29. To date, such strains appear to be absent in the U.S. For this reason, our report of NU-CRE265, a CR-KP strain with features of hvKP, is concerning. Two possible mechanisms for the evolution of these strains are the transfer of plasmids encoding extended-spectrum β-lactamases and carbapenemases to hvKP strains and the horizontal transfer of virulence genes from hvKP to multidrug-resistant KP strains. For example ybt genes, which encode for the hvKP siderophore yersiniabactin, can be horizontally acquired33; these siderophore genes have recently been noted in a number of carbapenemase-producing ST258 isolates33. ST258 strains account for the majority of CR-KP isolates around the globe61. One of the strains in our study, NU-CRE212, is an ST258 strain that contained the ybt genes (Table 2). Although NU-CR212 had low levels of virulence in both mouse models of infection, the acquisition of ybt genes by this strain suggests that CR-KP strains have the potential to acquire virulence genes, a process that could eventually lead to the ability to cause invasive and aggressive infections. These results add to recent reports suggesting that CR-KP strains with increased virulence are emerging and that studies to assess the epidemiology of CR-KP/hvKP are necessary not only in Asia but also in the U.S.
Methods
Identification of patients and bacterial isolates
We performed a retrospective study of all cases of CR-KP NSSTI diagnosed among adult patients hospitalized at a tertiary U.S. hospital from January 2012 to January 2016. CR-KP NSSTI cases were defined as skin or soft tissue infection with a necrotizing component confirmed by pathology or by surgical reports and tissue cultures positive for KP resistant to at least one carbapenem. For identified cases, the corresponding CR-KP isolates were recovered from a collection of multidrug-resistant isolates archived as part of the routine Institutional Infection Control Policy. NTUH-K2044, a well-characterized hvKP strain, and MGH78578, a well-characterized KP strain with low virulence potential, were used as controls38. This study was approved by the Northwestern University Institutional Review Board with a waiver of informed consent due to the retrospective nature of the study. No diagnostic or treatment decisions were affected by this study.
Clinical and microbiological data
Demographic and clinical data were obtained by chart review. Immunosuppression was defined as receiving chemotherapy or immunosuppressive drugs in the last month. Charlson score and modified sequential organ failure assessment (SOFA) score were used to estimate the level of comorbidities and severity of disease, respectively62,63. Adequate surgical treatment was defined as surgical debridement that achieved elimination of necrotic tissue. Antibiotic susceptibility data were determined by Vitek according to CLSI breakpoints64. Adequate antibiotic treatment was defined as administration for at least 24 hours of an antibiotic with activity against the cultured KP isolate based on the in vitro susceptibility results. Evaluated outcomes included length of hospital stay, relapse, and death. Relapse was defined as the recurrence of a skin or soft tissue infection within 6 months after completion of the antibiotic course at the same site of the initial infection and with a strain of the same species and susceptibility results as the index strain.
Growth media and culture conditions
KP strains were cultured at 37 °C in Luria-Bertani (LB) broth with shaking or on LB agar. When applicable, LB medium was supplemented with 50 μg/mL apramycin. For Lambda Red mutagenesis, strains were cultured at 30 °C in low salt LB65 supplemented with 100 μg/mL of hygromcyin B and 0.1 M L-arabinose.
Evaluation of hypermucoviscosity
A string test was used to assess for hypermucoviscosity in each CR-KP NSSTI isolate44. Briefly, isolates were grown overnight on LB agar. A single colony was lifted with a loop to evaluate for the formation and length of a viscous string between the loop and the colony. A positive string test was defined as a string length ≥ 5 mm. This test was performed twice for each strain for confirmation of the results.
Measurement of capsule production
Capsule production was measured by quantification of uronic acid extracted from equivalent volumes of overnight cultures, as previously reported66. Briefly, extracted samples from 500 μL of overnight cultures were resuspended in water and combined with 1.2 mL sodium tetraborate in concentrated sulfuric acid. Samples were boiled for 5 min, followed by the addition of 20 μL 0.15% 3-hydroxydiphenol in 0.5% NaOH, and the absorbance was measured at 520 nm. CPS levels were determined from a standard curve of D-glucuronic acid (Sigma-Aldrich, St. Louis, MO). Samples were normalized to the total viable bacteria in the culture (micrograms uronic acid/106 CFU) and were measured in triplicate.
Whole genome sequencing
NSSTI isolates were grown overnight in LB broth with shaking at 37 °C. DNA extraction was performed using Promega Maxwell 16 instrument (Madison, WI). Extracted DNA was processed for DNA library preparation and indexing using the Nextera XT kit (Illumina, San Diego, CA). DNA libraries were then evaluated using the Agilent Bioanalyzer 2100 to determine the DNA fragment size and the Quant-iT dsDNA High-Sensitivity Assay Kit to determine the DNA concentration. Equal amounts of each library were then pooled and run on the Illumina MiSeq system with 300-bp paired-end reads. Raw sequence reads were assembled de novo using SPAdes 3.5.067. Sequencing and assembling were performed blinded to the clinical data and the results of the in vitro and in vivo assays.
Molecular typing
Assembled whole genome sequences of the four CR-KP NSSTI isolates were analyzed with the publicly available bioinformatics tool MLST 1.8 (Center for Genomic Epidemiology)68 to determine their in silico MLST. In silico CPS genotyping was performed by aligning the assembled genome sequences of the four NSSTI isolates against a published database of wzc sequences linked to capsular serotypes35 using BLAST69.
Identification of virulence genes and antibiotic resistance genes
BLAST was used to align de-novo assembled genome sequences against the NCBI Bacterial Antimicrobial Resistance Reference Gene Database (http://www.ncbi.nlm.nih.gov/bioproject/PRJNA313047), ResFinder (http://www.genomicepidemiology.org 70), and the Pasteur database of virulence genes (http://bigsdb.pasteur.fr/klebsiella/klebsiella.html). Antibiotic resistance genes investigated included carbapenemases and other ß-lactamase genes. Virulence genes previously associated with hvKP were searched, including hypermucoviscosity-associated genes (rmpA/A2); genes associated with iron acquisition systems (aerobactin, yersiniabactin, enterobactin, salmochelin, and kfu), fimbrial genes (mrkD, fimH), colibactin genotoxin genes, and allantoin metabolism genes. Thresholds of ≥95% sequence identity and ≥50% gene length were used to detect the target genes. Identified virulence genes were confirmed by aligning each CR-KP NSSTI sequence with NTUH-K2044 and plasmid pK2044 sequences and verifying that the virulence genes detected by our screen had ≥ 95% similarity to the corresponding genes annotated for NTUH-K2044 (Accession number AP006725.1 and AP006726.1).
Macrophage uptake assay
Resistance to phagocytosis was assessed using a murine macrophage uptake assay38. Briefly, J774.A1 macrophage-like cells were cultured in DMEM (Invitrogen, Grand Island, NY) supplemented with heat-inactivated 10% fetal bovine serum and seeded into 24-well microtiter plates at a density of 1 × 105 cells per well. Cells were infected at an MOI of 10 with each KP strain. At 1 h post infection, amikacin (1 mg/mL) was added to the media, and the cells were incubated for 1 h to eradicate extracellular bacteria. Amikacin concentrations were empirically determined to kill extracellular KP in DMEM at >99.99% efficiency within the incubation period. Cell monolayers were washed with PBS, lysed with 0.2% saponin, and the number of intracellular bacteria enumerated by plating for viable CFU. Assays were performed in triplicate.
Mouse pneumonia model
Respiratory infections were performed as previously described42. Mice were anaesthetized via intraperitoneal administration of ketamine (100 mg/mL) and xylazine (20 mg/mL), and then infected with either 5 × 106 or 5 × 107 CFU of each strain diluted in 50 μL of PBS via intranasal administration. Mouse survival was monitored daily up to 14 days. Subgroups of infected mice were euthanized at specific time points (48 and 96 h post-infection) for quantification of bacterial burden in the lungs and the liver. The lungs and livers were excised and homogenized in PBS, and the viable bacteria enumerated by plating serial dilutions. Of note, the inoculum dose for mice infected with the highly virulent NTUH-K2044 strain was decreased to 1 × 103 CFU to allow survival out to 96 h post-infection.
Mouse subcutaneous infection model
Subcutaneous infections were performed as previously described39. Briefly, mice were anesthetized by intraperitoneal injection with a mixture of ketamine and xylazine, shaved in the area of the rear flank, and infected via subcutaneous injection of approximately 5 × 106 CFU of each KP strain diluted in 50 μL PBS. The apparent area of the abscess was quantified daily at the skin surface by multiplying the length of the long and short axes. Subgroups of mice were euthanized at 48 and 96 h post-infection for quantification of bacterial CFU within the abscess and the liver. A standardized surface area of 10 × 10 mm around the initial injection site was excised to a depth of 1 cm. This approach routinely captured the largest abscesses. Livers were aseptically removed from the same mice. Samples were homogenized in PBS, and the viable bacteria quantified by plating serial dilutions.
For neutrophil depletion, mice were injected intraperitoneally with 50 μg of either anti-Ly6G antibody (clone 1A8; BioXCell) or an IgG2A isotype control antibody (2A3; BioXCell) at 1 day prior to infection and again at 1 day post-infection. Mice were infected subcutaneously with approximately 5 × 106 CFU of each KP strain, and the abscess area and bacterial burdens measured.
Animals were purchased from Harlan Laboratories and housed in the containment ward of the Center for Comparative Medicine at Northwestern University. Female C57Bl/6 mice (6- to 10-week-old) were used for all experiments. Experiments were approved by and performed in accordance with the guidelines of the Northwestern University Animal Care and Use Committee.
Statistical Analysis
Statistical analysis was performed using Student T-test and analysis of variance (ANOVA) followed by the Bonferroni’s correction for multiple comparisons for parametric variables, and the Mann-Whitney U test for non-parametric variables. Statistical significance was defined as p ≤ 0.05.
Data Availability
The Whole Genome Shotgun projects of the NSSTI CR-KP isolates NU-CRE265, NU-CRE212, NU-CRE176, and NU-CRE101 have been deposited at DDBJ/ENA/GenBank under the accession numbers: NQLL00000000.1, NQLM00000000.1, NQLN00000000.1, NQLO00000000.1, respectively). The datasets and materials generated during the current study are available from the corresponding author on reasonable request.
Electronic supplementary material
Acknowledgements
The authors thank Chao Qi and the staff of the Clinical Microbiological Laboratory and Teresa Zembower and the Healthcare Epidemiology and Infection Prevention Committee of Northwestern Memorial Hospital for their technical support in performing this study. This work was supported by National Institute of Allergy and Infectious Diseases (NIAID) grants K24 AI104831, R01 AI053674, R01 AI118257, and matching funds from the Department of Medicine, Feinberg School of Medicine, Northwestern University for T32 AI095207.
Author Contributions
F.K. and A.R.M. contributed equally to this work. F.K. performed the retrospective review of clinical data and the genomic analysis; A.R.M. designed and performed the experiments and both F.K. and A.R.M. analyzed the data and wrote the main manuscript text. E.A.O. contributed with the bioinformatics analyses. A.R.H. supervised the study and provided advice at all stages. All authors discussed the results and implications of this work and edited the manuscript.
Competing Interests
The authors declare that they have no competing interests.
Footnotes
Fiorella Krapp and Andrew R. Morris contributed equally to this work.
Electronic supplementary material
Supplementary information accompanies this paper at 10.1038/s41598-017-13524-8.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Fiorella Krapp, Email: fiorella.krapp@northwestern.edu.
Andrew R. Morris, Email: andrew.morris1@northwestern.edu
References
- 1.Shon AS, Bajwa RP, Russo TA. Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: a new and dangerous breed. Virulence. 2013;4:107–118. doi: 10.4161/viru.22718. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Lin YT, et al. Pyogenic liver abscess as the initial manifestation of underlying hepatocellular carcinoma. Am J Med. 2011;124:1158–1164. doi: 10.1016/j.amjmed.2011.08.012. [DOI] [PubMed] [Google Scholar]
- 3.Hsieh PF, Lin TL, Lee CZ, Tsai SF, Wang JT. Serum-induced iron-acquisition systems and TonB contribute to virulence in Klebsiella pneumoniae causing primary pyogenic liver abscess. J Infect Dis. 2008;197:1717–1727. doi: 10.1086/588383. [DOI] [PubMed] [Google Scholar]
- 4.Cheng NC, et al. Recent trend of necrotizing fasciitis in Taiwan: focus on monomicrobial Klebsiella pneumoniae necrotizing fasciitis. Clin Infect Dis. 2012;55:930–939. doi: 10.1093/cid/cis565. [DOI] [PubMed] [Google Scholar]
- 5.Chang L, Bastian I, Warner M. Survey of Klebsiella pneumoniae bacteraemia in two South Australian hospitals and detection of hypermucoviscous phenotype and magA/rmpA genotypes in K. pneumoniae isolates. Infection. 2013;41:559–563. doi: 10.1007/s15010-012-0374-y. [DOI] [PubMed] [Google Scholar]
- 6.Keynan Y, Karlowsky JA, Walus T, Rubinstein E. Pyogenic liver abscess caused by hypermucoviscous Klebsiella pneumoniae. Scand J Infect Dis. 2007;39:828–830. doi: 10.1080/00365540701266763. [DOI] [PubMed] [Google Scholar]
- 7.Fierer J, Walls L, Chu P. Recurring Klebsiella pneumoniae pyogenic liver abscesses in a resident of San Diego, California, due to a K1 strain carrying the virulence plasmid. J Clin Microbiol. 2011;49:4371–4373. doi: 10.1128/JCM.05658-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Liu YM, et al. Microbiology and factors affecting mortality in necrotizing fasciitis. J Microbiol Immunol Infect. 2005;38:430–435. [PubMed] [Google Scholar]
- 9.Bernal NP, Latenser BA, Born JM, Liao J. Trends in 393 necrotizing acute soft tissue infection patients 2000–2008. Burns. 2012;38:252–260. doi: 10.1016/j.burns.2011.07.008. [DOI] [PubMed] [Google Scholar]
- 10.Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998;11:589–603. doi: 10.1128/cmr.11.4.589. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Yu WL, et al. Comparison of prevalence of virulence factors for Klebsiella pneumoniae liver abscesses between isolates with capsular K1/K2 and non-K1/K2 serotypes. Diagn Microbiol Infect Dis. 2008;62:1–6. doi: 10.1016/j.diagmicrobio.2008.04.007. [DOI] [PubMed] [Google Scholar]
- 12.Chen YT, et al. Sequencing and analysis of the large virulence plasmid pLVPK of Klebsiella pneumoniae CG43. Gene. 2004;337:189–198. doi: 10.1016/j.gene.2004.05.008. [DOI] [PubMed] [Google Scholar]
- 13.Russo TA, et al. Aerobactin mediates virulence and accounts for increased siderophore production under iron-limiting conditions by hypervirulent (hypermucoviscous) Klebsiella pneumoniae. Infect Immun. 2014;82:2356–2367. doi: 10.1128/IAI.01667-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Lin TL, Lee CZ, Hsieh PF, Tsai SF, Wang JT. Characterization of integrative and conjugative element ICEKp1-associated genomic heterogeneity in a Klebsiella pneumoniae strain isolated from a primary liver abscess. J Bacteriol. 2008;190:515–526. doi: 10.1128/JB.01219-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Ma LC, Fang CT, Lee CZ, Shun CT, Wang JT. Genomic heterogeneity in Klebsiella pneumoniae strains is associated with primary pyogenic liver abscess and metastatic infection. J Infect Dis. 2005;192:117–128. doi: 10.1086/430619. [DOI] [PubMed] [Google Scholar]
- 16.Struve C, et al. Mapping the Evolution of Hypervirulent Klebsiella pneumoniae. MBio. 2015;6:e00630. doi: 10.1128/mBio.00630-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Pomakova DK, et al. Clinical and phenotypic differences between classic and hypervirulent Klebsiella pneumoniae: an emerging and under-recognized pathogenic variant. Eur J Clin Microbiol Infect Dis. 2012;31:981–989. doi: 10.1007/s10096-011-1396-6. [DOI] [PubMed] [Google Scholar]
- 18.Fang, C. T. et al. Klebsiella pneumoniae genotype K1: an emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess. Clin Infect Dis45, 284–293, 10.1086/519262 (2007). [DOI] [PubMed]
- 19.Lin YT, Jeng YY, Chen TL, Fung CP. Bacteremic community-acquired pneumonia due to Klebsiella pneumoniae: clinical and microbiological characteristics in Taiwan, 2001-2008. BMC Infect Dis. 2010;10:307. doi: 10.1186/1471-2334-10-307. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Ko WC, et al. Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis. 2002;8:160–166. doi: 10.3201/eid0802.010025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25:682–707. doi: 10.1128/CMR.05035-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Qureshi ZA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56:2108–2113. doi: 10.1128/AAC.06268-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Tzouvelekis LS, et al. KPC-producing, multidrug-resistant Klebsiella pneumoniae sequence type 258 as a typical opportunistic pathogen. Antimicrob Agents and Chemother. 2013;57:5144–5146. doi: 10.1128/AAC.01052-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Rana MM, Sturdevant M, Patel G, Huprikar S. Klebsiella necrotizing soft tissue infections in liver transplant recipients: a case series. Transpl Infect Dis. 2013;15:E157–163. doi: 10.1111/tid.12103. [DOI] [PubMed] [Google Scholar]
- 25.Yao B, et al. Clinical and molecular characteristics of multi-clone carbapenem-resistant hypervirulent (hypermucoviscous) Klebsiella pneumoniae isolates in a tertiary hospital in Beijing, China. Int J Infect Dis. 2015;37:107–112. doi: 10.1016/j.ijid.2015.06.023. [DOI] [PubMed] [Google Scholar]
- 26.Zhang R, et al. Emergence of Carbapenem-Resistant Serotype K1 Hypervirulent Klebsiella pneumoniae Strains in China. Antimicrob Agents Chemother. 2015;60:709–711. doi: 10.1128/AAC.02173-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Andrade LN, et al. Expansion and evolution of a virulent, extensively drug-resistant (polymyxin B-resistant), QnrS1-, CTX-M-2-, and KPC-2-producing Klebsiella pneumoniae ST11 international high-risk clone. J Clin Microbio. 2014;52:2530–2535. doi: 10.1128/JCM.00088-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Cejas D, et al. First isolate of KPC-2-producing Klebsiella pneumonaie sequence type 23 from the Americas. J Clin Microbiol. 2014;52:3483–3485. doi: 10.1128/JCM.00726-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Zhang Y, et al. Emergence of a hypervirulent carbapenem-resistant Klebsiella pneumoniae isolate from clinical infections in China. J Infect. 2015;71:553–560. doi: 10.1016/j.jinf.2015.07.010. [DOI] [PubMed] [Google Scholar]
- 30.Arena F, et al. Large oligoclonal outbreak due to Klebsiella pneumoniae ST14 and ST26 producing the FOX-7 AmpC beta-lactamase in a neonatal intensive care unit. J Clin Microbiol. 2013;51:4067–4072. doi: 10.1128/JCM.01982-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Lee CR, et al. Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods. Front Microbiol. 2016;7:895. doi: 10.3389/fmicb.2016.00895. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012;18:263–272. doi: 10.1016/j.molmed.2012.03.003. [DOI] [PubMed] [Google Scholar]
- 33.Holt KE, et al. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. Proc Natl Acad Sci USA. 2015;112:E3574–3581. doi: 10.1073/pnas.1501049112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Yeh KM, et al. Capsular serotype K1 or K2, rather than magA and rmpA, is a major virulence determinant for Klebsiella pneumoniae liver abscess in Singapore and Taiwan. J Clin Microbiol. 2007;45:466–471. doi: 10.1128/JCM.01150-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Pan YJ, et al. Capsular types of Klebsiella pneumoniae revisited by wzc sequencing. PloS one. 2013;8:e80670. doi: 10.1371/journal.pone.0080670. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Kabha K, et al. Relationships among capsular structure, phagocytosis, and mouse virulence in Klebsiella pneumoniae. Infect immun. 1995;63:847–852. doi: 10.1128/iai.63.3.847-852.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Lin JC, et al. High prevalence of phagocytic-resistant capsular serotypes of Klebsiella pneumoniae in liver abscess. Microbes Infect. 2004;6:1191–1198. doi: 10.1016/j.micinf.2004.06.003. [DOI] [PubMed] [Google Scholar]
- 38.Fodah RA, et al. Correlation of Klebsiella pneumoniae comparative genetic analyses with virulence profiles in a murine respiratory disease model. PloS one. 2014;9:e107394. doi: 10.1371/journal.pone.0107394. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Simoons-Smit AM, Verwey-van Vught AM, Kanis IY, MacLaren DM. Virulence of Klebsiella strains in experimentally induced skin lesions in the mouse. J Med Microbiol. 1984;17:67–77. doi: 10.1099/00222615-17-1-67. [DOI] [PubMed] [Google Scholar]
- 40.Bullen JJ, Leach PA, Lange L. Abolition of resistance to Klebsiella pneumoniae by anti-polymorphonuclear leucocyte IgG. Immunology. 1980;39:47–52. [PMC free article] [PubMed] [Google Scholar]
- 41.Fukutome T, Mitsuyama M, Takeya K, Nomoto K. Importance of antiserum and phagocytic cells in the protection of mice against infection by Klebsiella pneumoniae. J Gen Microbiol. 1980;119:225–229. doi: 10.1099/00221287-119-1-225. [DOI] [PubMed] [Google Scholar]
- 42.Lawlor MS, Hsu J, Rick PD, Miller VL. Identification of Klebsiella pneumoniae virulence determinants using an intranasal infection model. Mol Microbiol. 2005;58:1054–1073. doi: 10.1111/j.1365-2958.2005.04918.x. [DOI] [PubMed] [Google Scholar]
- 43.Cubero M, et al. Hypervirulent Klebsiella pneumoniae clones causing bacteraemia in adults in a teaching hospital in Barcelona, Spain (2007-2013) Clin Microbiol Infect. 2016;22:154–160. doi: 10.1016/j.cmi.2015.09.025. [DOI] [PubMed] [Google Scholar]
- 44.Fang CT, Chuang YP, Shun CT, Chang SC, Wang JT. A novel virulence gene in Klebsiella pneumoniae strains causing primary liver abscess and septic metastatic complications. J Exp Med. 2004;199:697–705. doi: 10.1084/jem.20030857. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Lawlor MS, O’Connor C, Miller VL. Yersiniabactin is a virulence factor for Klebsiella pneumoniae during pulmonary infection. Infect Immun. 2007;75:1463–1472. doi: 10.1128/IAI.00372-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Nassif X, Fournier JM, Arondel J, Sansonetti PJ. Mucoid phenotype of Klebsiella pneumoniae is a plasmid-encoded virulence factor. Infect immun. 1989;57:546–552. doi: 10.1128/iai.57.2.546-552.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Hsieh PF, Lin TL, Lee CZ, Tsai SF, Wang JT. Serum-induced iron-acquisition systems and TonB contribute to virulence in Klebsiella pneumoniae causing primary pyogenic liver abscess. J Infect Dis. 2008;197:1717–1727. doi: 10.1086/588383. [DOI] [PubMed] [Google Scholar]
- 48.Russo TA, et al. Hypervirulent K. pneumoniae secretes more and more active iron-acquisition molecules than “classical” K. pneumoniae thereby enhancing its virulence. PLoS One. 2011;6:e26734. doi: 10.1371/journal.pone.0026734. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Yu WL, et al. Comparison of prevalence of virulence factors for Klebsiella pneumoniae liver abscesses between isolates with capsular K1/K2 and non-K1/K2 serotypes. Diagn. Microbiol. Infect. Dis. 2008;62:1–6. doi: 10.1016/j.diagmicrobio.2008.04.007. [DOI] [PubMed] [Google Scholar]
- 50.Yu VL, et al. Virulence characteristics of Klebsiella and clinical manifestations of K. pneumoniae bloodstream infections. Emerg. Infect. Dis. 2007;13:986–993. doi: 10.3201/eid1307.070187. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Lau HY, Clegg S, Moore TA. Identification of Klebsiella pneumoniae genes uniquely expressed in a strain virulent using a murine model of bacterial pneumonia. Microb Pathog. 2007;42:148–155. doi: 10.1016/j.micpath.2007.01.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Yan Q, Zhou M, Zou M, Liu WE. Hypervirulent Klebsiella pneumoniae induced ventilator-associated pneumonia in mechanically ventilated patients in China. Eur J Clin Microbiol Infect Dis. 2016;35:387–396. doi: 10.1007/s10096-015-2551-2. [DOI] [PubMed] [Google Scholar]
- 53.Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG., Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28:603–661. doi: 10.1128/CMR.00134-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Hakkarainen TW, Kopari NM, Pham TN, Evans HL. Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes. Curr Probl Surg. 2014;51:344–362. doi: 10.1067/j.cpsurg.2014.06.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.El Fertas-Aissani R, Messai Y, Alouache S, Bakour R. Virulence profiles and antibiotic susceptibility patterns of Klebsiella pneumoniae strains isolated from different clinical specimens. Pathol Biol (Paris) 2013;61:209–216. doi: 10.1016/j.patbio.2012.10.004. [DOI] [PubMed] [Google Scholar]
- 56.Guo Y, et al. Microbiological and Clinical Characteristics of Hypermucoviscous Klebsiella pneumoniae Isolates Associated with Invasive Infections in China. Front Cell Infect Microbiol. 2017;7:24. doi: 10.3389/fcimb.2017.00024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Wasfi R, Elkhatib WF, Ashour HM. Molecular typing and virulence analysis of multidrug resistant Klebsiella pneumoniae clinical isolates recovered from Egyptian hospitals. Sci Rep. 2016;6:38929. doi: 10.1038/srep38929. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Bachman, M. A., Lenio, S., Schmidt, L., Oyler, J. E. & Weiser, J. N. Interaction of lipocalin 2, transferrin, and siderophores determines the replicative niche of Klebsiella pneumoniae during pneumonia. MBio3, 10.1128/mBio.00224-11 (2012). [DOI] [PMC free article] [PubMed]
- 59.Bachman MA, et al. Klebsiella pneumoniae yersiniabactin promotes respiratory tract infection through evasion of lipocalin 2. Infection and immunity. 2011;79:3309–3316. doi: 10.1128/IAI.05114-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Lery LM, et al. Comparative analysis of Klebsiella pneumoniae genomes identifies a phospholipase D family protein as a novel virulence factor. BMC Biol. 2014;12:41. doi: 10.1186/1741-7007-12-41. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Chen L, et al. Carbapenemase-producing Klebsiella pneumoniae: molecular and genetic decoding. Trends Microbiol. 2014;22:686–696. doi: 10.1016/j.tim.2014.09.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383. doi: 10.1016/0021-9681(87)90171-8. [DOI] [PubMed] [Google Scholar]
- 63.Vincent JL, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–710. doi: 10.1007/BF01709751. [DOI] [PubMed] [Google Scholar]
- 64.CLSI. in CLSI supplement M100 (Clinical and Laboratory Standards Institute, Wayne, PA, 2016).
- 65.Huang TW, et al. Capsule deletion via a lambda-Red knockout system perturbs biofilm formation and fimbriae expression in Klebsiella pneumoniae MGH 78578 BMC Res Note. J Clin Microbiol. 2014;7:13. doi: 10.1186/1756-0500-7-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Domenico P, Schwartz S, Cunha BA. Reduction of capsular polysaccharide production in Klebsiella pneumoniae by sodium salicylate. Infect immun. 1989;57:3778–3782. doi: 10.1128/iai.57.12.3778-3782.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Bankevich A, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19:455–477. doi: 10.1089/cmb.2012.0021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Larsen MV, et al. Multilocus sequence typing of total-genome-sequenced bacteria. J Clin Microbiol. 2012;50:1355–1361. doi: 10.1128/JCM.06094-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215:403–410. doi: 10.1016/S0022-2836(05)80360-2. [DOI] [PubMed] [Google Scholar]
- 70.Zankari E, et al. Identification of acquired antimicrobial resistance genes. JAntimicrobial Chemother. 2012;67:2640–2644. doi: 10.1093/jac/dks261. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The Whole Genome Shotgun projects of the NSSTI CR-KP isolates NU-CRE265, NU-CRE212, NU-CRE176, and NU-CRE101 have been deposited at DDBJ/ENA/GenBank under the accession numbers: NQLL00000000.1, NQLM00000000.1, NQLN00000000.1, NQLO00000000.1, respectively). The datasets and materials generated during the current study are available from the corresponding author on reasonable request.